Keystone Resort Floorplan
Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
This meeting took place in 2019
Here are the related meetings in 2023:
Neurodegeneration: New Biology Guiding the Next Generation of Therapeutic Development (Z4)
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
Neurodegenerative Diseases: New Insights and Therapeutic Opportunities (Z2)
Organizer(s) Valina L. Dawson, Joseph W. Lewcock and Fred H. Gage
June 16—20, 2019
Keystone Resort • Keystone, CO USA
Discounted Abstract Deadline: Feb 13, 2019
Abstract Deadline: Mar 13, 2019
Scholarship Deadline: Feb 13, 2019
Discounted Registration Deadline: Apr 16, 2019
Sponsored by BioLegend, Inc., Biogen, BlueRock Therapeutics, Genentech, Inc., Ionis Pharmaceuticals, Inc., Roche and Takeda Pharmaceutical Company Limited
Summary of Meeting:
The global burden of neurodegenerative disease is staggering and growing at an alarming rate as the population ages. While Alzheimer’s disease and related dementias, as well as, Parkinson’s disease and related disorders, account for the majority of those afflicted, there are also less common but equally devastating diseases. Technical and conceptual advances are revealing disease mechanisms and providing new therapeutic opportunities. Misfolded proteins have been understood to be at the center of neurodegenerative diseases but recently there is an appreciation that these misfolded proteins may serve as seeds to template the misfolding of normal proteins, that transmission of these seeds may underlie disease progression, and that there may be different strains of these seeds with differential toxicities. Biophysical analysis of these proteins reveals a role for phase transition and liquid demixing of these intrinsically disordered proteins. Synaptic loss is an important feature of neurodegeneration which may occur long before neuronal loss, but be critically important in disease presentation and loss of function. Glia and immune activation contribute to neurodegeneration and synaptic loss, and must be understood and controlled if the disease process is to be tempered or stopped. This conference aims to address the current state of knowledge in these emerging area and to provide advanced discussion of these topics; the opportunity for interaction between scientists from different fields of research will foster new collaborations that may lead to new therapeutic opportunities to combat the coming crisis and provide medical care for those suffering from neurodegenerative diseases.
View Scholarships/Awards
The global burden of neurodegenerative disease is staggering and growing at an alarming rate as the population ages. While Alzheimer’s disease and related dementias, as well as, Parkinson’s disease and related disorders, account for the majority of those afflicted, there are also less common but equally devastating diseases. Technical and conceptual advances are revealing disease mechanisms and providing new therapeutic opportunities. Misfolded proteins have been understood to be at the center of neurodegenerative diseases but recently there is an appreciation that these misfolded proteins may serve as seeds to template the misfolding of normal proteins, that transmission of these seeds may underlie disease progression, and that there may be different strains of these seeds with differential toxicities. Biophysical analysis of these proteins reveals a role for phase transition and liquid demixing of these intrinsically disordered proteins. Synaptic loss is an important feature of neurodegeneration which may occur long before neuronal loss, but be critically important in disease presentation and loss of function. Glia and immune activation contribute to neurodegeneration and synaptic loss, and must be understood and controlled if the disease process is to be tempered or stopped. This conference aims to address the current state of knowledge in these emerging area and to provide advanced discussion of these topics; the opportunity for interaction between scientists from different fields of research will foster new collaborations that may lead to new therapeutic opportunities to combat the coming crisis and provide medical care for those suffering from neurodegenerative diseases.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
The meeting will begin on Sunday, June 16 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, June 20 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, June 21 in order to fully experience the meeting.
SUNDAY, JUNE 16
MONDAY, JUNE 17
TUESDAY, JUNE 18
WEDNESDAY, JUNE 19
THURSDAY, JUNE 20
FRIDAY, JUNE 21
Conference Program Print | View meeting in 12 hr (am/pm) time
The meeting will begin on Sunday, June 16 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, June 20 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, June 21 in order to fully experience the meeting.
SUNDAY, JUNE 16
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.
08:30—09:30
Welcome and Keynote Address
*
Fred H. Gage,
The Salk Institute for Biological Studies, USA
Session Chair
Session Chair
Marc Tessier-Lavigne,
Stanford University, USA
Molecular Control of Axon Degeneration in Development, Disease and Adult Plasticity
Molecular Control of Axon Degeneration in Development, Disease and Adult Plasticity
08:30—09:30
Welcome and Keynote Address
*
Richard Daneman,
University of California, San Diego, USA
Session Chair
Session Chair
*
Dorothy Schafer,
University of Massachusetts Chan Medical School, USA
Session Chair
Session Chair
Li-Huei Tsai,
Massachusetts Institute of Technology, USA
Neuron-Glia Interaction in Health and Disease
Neuron-Glia Interaction in Health and Disease
09:30—11:45
Aggregation Mediated Toxicity
*
Xiaobo Mao,
Johns Hopkins University, USA
Session Chair
Session Chair
Rudolph E. Tanzi,
Massachusetts General Hospital, USA
Amyloid Beta Organoid Model
Amyloid Beta Organoid Model
Coffee Break
Thomas Brannstrom,
Umea University Hospital, Sweden
Short Talk: Transmissibility of SOD1 Prion Strains Between Mice Expressing Different Mutant Human SOD1s
Short Talk: Transmissibility of SOD1 Prion Strains Between Mice Expressing Different Mutant Human SOD1s
09:30—12:00
Neuronal Response to Injury
*
David M. Holtzman,
Washington University, USA
TREM2 Function Regulates Aβ linked Tau Seeding and Spreading in Neuritic Plaques
TREM2 Function Regulates Aβ linked Tau Seeding and Spreading in Neuritic Plaques
Coffee Break
Eric J. Huang,
University of California, San Francisco, USA
Neuron-Glia Interaction in Human Germinal Matrix: Implications in Neurodevelopmental Disorders
Neuron-Glia Interaction in Human Germinal Matrix: Implications in Neurodevelopmental Disorders
Katie Ennis,
Biogen, USA
Short Talk: The Cytokine Receptor Fn14 is Required for Hippocampal Synaptic Plasticity Deficits that Occur Following Acute Ischemic Stroke
Short Talk: The Cytokine Receptor Fn14 is Required for Hippocampal Synaptic Plasticity Deficits that Occur Following Acute Ischemic Stroke
Lucas Cheadle,
Harvard Medical School, USA
Short Talk: Sensory Experience Engages Microglia-to-Neuron Cytokine Signaling to Remodel Developing Synapses
Short Talk: Sensory Experience Engages Microglia-to-Neuron Cytokine Signaling to Remodel Developing Synapses
15:00—16:30
Workshop 1
*
David V. Hansen,
Brigham Young University, USA
Session Chair
Session Chair
Michael Henderson,
University of Pennsylvania, USA
Using Quantitative Pathology Mapping and Network Modeling to Understand α-Synuclein Spread
Using Quantitative Pathology Mapping and Network Modeling to Understand α-Synuclein Spread
Sang Su Kwak,
Genetics and Aging Research Unit, Massachusetts General Hospital, USA
Amyloid-β 42/40 Ratio Drives Tau Pathology in 3D Human Neural Cell Culture Models of Alzheimer's Disease
Amyloid-β 42/40 Ratio Drives Tau Pathology in 3D Human Neural Cell Culture Models of Alzheimer's Disease
Evan T. Lester,
University of Colorado, USA
Interactions between RNA and Tau in Models of Frontotemporal Dementia
Interactions between RNA and Tau in Models of Frontotemporal Dementia
Sílvia Porta,
Center for Neurodegenerative Disease Research, USA
Patient-Derived Frontotemporal Lobar Degeneration Brain Extracts Induce Formation and Spreading of TDP-43 Pathology in vivo
Patient-Derived Frontotemporal Lobar Degeneration Brain Extracts Induce Formation and Spreading of TDP-43 Pathology in vivo
Stephanie K. See,
University of California, San Francisco, USA
Identification of Cellular Mechanisms that Control α-Synuclein Aggregation Using a CRISPRi/a Functional Genomics Platform
Identification of Cellular Mechanisms that Control α-Synuclein Aggregation Using a CRISPRi/a Functional Genomics Platform
Meghan Kerrisk Campbell,
Alkahest, USA
A Therapeutic Human Plasma Fraction Enhances Cognitive Function in Aging and Neurodegenerative Disease through Multiple Mechanisms of Action
A Therapeutic Human Plasma Fraction Enhances Cognitive Function in Aging and Neurodegenerative Disease through Multiple Mechanisms of Action
14:30—16:30
Workshop 1: Modulating Microglia Inflammatory Signaling
*
Kim N. Green,
University of California, Irvine, USA
Session Chair
Session Chair
*
Iben Lundgaard,
University of Lund, Sweden
Session Chair
Session Chair
Ying Cao,
Peking University, China
Transcriptional Mechanism of IRF8 and PU.1 Governs Microglial Activation in Neurodegenerative Condition
Transcriptional Mechanism of IRF8 and PU.1 Governs Microglial Activation in Neurodegenerative Condition
Rouven Schulz,
Institute of Science and Technology Austria, Austria
Topological Classification of Microglia
Topological Classification of Microglia
Yajing Xu,
University College London, UK
Microglia Mediate Restructuring of Spinal Somatosensory Circuits During Normal Postnatal Development and After Injury
Microglia Mediate Restructuring of Spinal Somatosensory Circuits During Normal Postnatal Development and After Injury
Youtong Huang,
University of California, San Diego / Salk Institute, USA
Investigating Microglial TAM Receptors as Modulators of Alzheimer's Pathology
Investigating Microglial TAM Receptors as Modulators of Alzheimer's Pathology
Guy C. Brown,
University of Cambridge, UK
Blocking the Microglial P2Y6 Receptor Prevents Microglial Phagocytosis of Neurons and Synapses, and Prevents Neurodegeneration Induced by Neuroinflammation, Beta Amyloid, TAU and Ageing in vivo
Blocking the Microglial P2Y6 Receptor Prevents Microglial Phagocytosis of Neurons and Synapses, and Prevents Neurodegeneration Induced by Neuroinflammation, Beta Amyloid, TAU and Ageing in vivo
Monique S. Mendes,
University of Rochester, USA
In vivo Imaging of Microglial Self-Renewal and Maturation in the Adult Mouse Brain
In vivo Imaging of Microglial Self-Renewal and Maturation in the Adult Mouse Brain
Sanda Mimouna,
Hospital for Special Surgery, USA
The Role of Transcriptional Coregulator GRIP1 in Myeloid Cells in Neuroinflammation
The Role of Transcriptional Coregulator GRIP1 in Myeloid Cells in Neuroinflammation
17:00—19:00
Transmission and Spread of Disease Pathology
*
Karen Hsiao Ashe,
University of Minnesota, USA
Session Chair
Session Chair
Xiaobo Mao,
Johns Hopkins University, USA
The Mechanism of Pathological alpha-synuclein Transmission
The Mechanism of Pathological alpha-synuclein Transmission
John Collinge,
University College London, UK
Prion Neurodegeneration: Towards an Effective Treatment and its Relevance for Alzheimer's Disease
Prion Neurodegeneration: Towards an Effective Treatment and its Relevance for Alzheimer's Disease
Karina Fog,
H. Lundbeck A/S, Denmark
Alpha-Synuclein Antibodies as Therapeutics in Synucleinopathies – How Antibodies Affect Cellular Handling of Misfolded alpha-synuclein
Alpha-Synuclein Antibodies as Therapeutics in Synucleinopathies – How Antibodies Affect Cellular Handling of Misfolded alpha-synuclein
Amanda Engstrom,
Emory University, USA
Short Talk: Pathological Tau Induces Neurodegeneration Through the Sequestration and Inhibition of LSD1 Function
Short Talk: Pathological Tau Induces Neurodegeneration Through the Sequestration and Inhibition of LSD1 Function
Xuyuan Kuang,
Rutgers University, USA
Short Talk: Association of Transmissive PolyQ Aggregates with Lipid Vesicles and Its Implications in Mutant Huntingtin Seeding
Short Talk: Association of Transmissive PolyQ Aggregates with Lipid Vesicles and Its Implications in Mutant Huntingtin Seeding
17:00—19:00
Astrocytes
Michael V. Sofroniew,
University of California, Los Angeles, USA
Astrocyte Roles in Repair and Regeneration
Astrocyte Roles in Repair and Regeneration
Blanca Diaz Castro,
University of Edinburgh, UK
Striatal Astrocytes: Identity, Form, Function and Roles in Huntington's Disease
Striatal Astrocytes: Identity, Form, Function and Roles in Huntington's Disease
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:30—11:45
New Therapeutic Opportunities
*
Joseph W. Lewcock,
Denali Therapeutics, USA
Session Chair
Session Chair
Frank Rigo,
Ionis Pharmaceuticals, USA
RNA Targeting Therapeutics for the Treatment of Neurodegenerative Diseases
RNA Targeting Therapeutics for the Treatment of Neurodegenerative Diseases
Eric J. Huang,
University of California, San Francisco, USA
Microglia Toxicity and TDP-43 Proteinopathy in Neurodegeneration
Microglia Toxicity and TDP-43 Proteinopathy in Neurodegeneration
Coffee Break
Don W. Cleveland,
University of California, San Diego, USA
Gene Silencing Therapy for Neurodegenerative Disease
Gene Silencing Therapy for Neurodegenerative Disease
Li Gan,
Weill Cornell Medicine, USA
Sex-Dimorphic Effects of Microglial Dysfunction in Neurodegeneration
Sex-Dimorphic Effects of Microglial Dysfunction in Neurodegeneration
Dieter Willbold,
Forschungszentrum Jülich, Germany
Short Talk: First Clinical Data of the First Anti-Prionic PRI-002 that is Orally Available, Reverts Cognition Deficits, and Decelerates Neurodegeneration in Transgenic AD Mouse Models
Short Talk: First Clinical Data of the First Anti-Prionic PRI-002 that is Orally Available, Reverts Cognition Deficits, and Decelerates Neurodegeneration in Transgenic AD Mouse Models
Daniel Heinzer,
University of Zurich, Switzerland
Short Talk: Whole Genome RNAi Screen Identifies Novel Regulators of PrPC as Potential Therapeutic Targets in Prion Diseases
Short Talk: Whole Genome RNAi Screen Identifies Novel Regulators of PrPC as Potential Therapeutic Targets in Prion Diseases
Alessandro Sette,
La Jolla Institute for Immunology, USA
Short Talk: T Cell Reactivity to Tau and Alpha-Synuclein in PD
Short Talk: T Cell Reactivity to Tau and Alpha-Synuclein in PD
08:30—11:45
Microglia and Innate Immunity
Dorothy Schafer,
University of Massachusetts Chan Medical School, USA
Targeting Microglia-Mediated Synapse Loss for Therapeutic Intervention in Multiple Sclerosis
Targeting Microglia-Mediated Synapse Loss for Therapeutic Intervention in Multiple Sclerosis
Kim N. Green,
University of California, Irvine, USA
Microglia Facilitate Plaque Development and Mediate the Downregulation of Synaptic Genes in Alzheimer's Disease Mice
Microglia Facilitate Plaque Development and Mediate the Downregulation of Synaptic Genes in Alzheimer's Disease Mice
Coffee Break
*
Anne Schaefer,
Icahn School of Medicine at Mount Sinai, MPI Ageing, USA
Epigenetic and Signaling Controlled Brain Region-Specific Microglia Functions
Epigenetic and Signaling Controlled Brain Region-Specific Microglia Functions
*
Francisco J. Quintana,
Harvard Medical School and the Broad Institute of MIT and Harvard, USA
Molecular Control of Astrocyte Pathogenic Activities in MS
Molecular Control of Astrocyte Pathogenic Activities in MS
Serena Becchi,
University of New South Wales, Australia
Short Talk: The Role of Microglia when Decision Making is Impaired by a High Fat and Sugar Diet in Rats
Short Talk: The Role of Microglia when Decision Making is Impaired by a High Fat and Sugar Diet in Rats
Manana Kutsia,
Okinawa Institute of Science and Technology Graduate University, Japan
Short Talk: Importance of Microglia for Neural Tissue Regeneration in Zebrafish Model of Traumatic Brain Injury
Short Talk: Importance of Microglia for Neural Tissue Regeneration in Zebrafish Model of Traumatic Brain Injury
Sandra Siegert,
Institute of Science and Technology Austria, Austria
Short Talk: Sex Specific Microglia Response to Transient Reduction of Neuronal Activity
Short Talk: Sex Specific Microglia Response to Transient Reduction of Neuronal Activity
17:00—19:00
Developing Effective Preclinical Disease Models
*
Valina L. Dawson,
Johns Hopkins University School of Medicine, USA
Session Chair
Session Chair
Martin Kampmann,
University of California, San Francisco, USA
Elucidating Cellular Mechanisms and Therapeutic Strategies for Neurodegenerative Diseases with Multimodal CRISPR-based Genetic Screens in iPSC-Derived Neurons and Glia
Elucidating Cellular Mechanisms and Therapeutic Strategies for Neurodegenerative Diseases with Multimodal CRISPR-based Genetic Screens in iPSC-Derived Neurons and Glia
Fred H. Gage,
The Salk Institute for Biological Studies, USA
iPSC to Study Repair and Neurodegeneration
iPSC to Study Repair and Neurodegeneration
Zhuohao He,
Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, China
Short Talk: Studying Tau Transmission in AD and FTLD Using Novel Mouse Models
Short Talk: Studying Tau Transmission in AD and FTLD Using Novel Mouse Models
17:00—19:00
Blood Brain Barrier
Richard Daneman,
University of California, San Diego, USA
Regulation of the Blood-Brain Barrier in Health and Disease
Regulation of the Blood-Brain Barrier in Health and Disease
*
Alexandre Prat,
Université de Montréal, Canada
Influence of Cytokines on the Blood-Brain Barrier
Influence of Cytokines on the Blood-Brain Barrier
*
Eric V. Shusta,
University of Wisconsin-Madison, USA
Modeling the Neurovascular Unit Using Human iPSCs
Modeling the Neurovascular Unit Using Human iPSCs
Sidar Aydin,
University of Bern, Switzerland
Short Talk: Endothelial Antigen-Presentation Stops the Migration of CD8+ T Cells Across the Blood-Brain Barrier in Neuroinflammation
Short Talk: Endothelial Antigen-Presentation Stops the Migration of CD8+ T Cells Across the Blood-Brain Barrier in Neuroinflammation
Matthew N. McCarroll,
University of California, San Francisco, USA
Short Talk: An Inducible Zebrafish Model of Pineal Gland Ablation Reveals Dynamics of Neuronal Cell Death, Regeneration and Microgliosis in vivo
Short Talk: An Inducible Zebrafish Model of Pineal Gland Ablation Reveals Dynamics of Neuronal Cell Death, Regeneration and Microgliosis in vivo
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:30—11:30
Translating Therapeutics for Neurodegeneration to the Clinic
*
Karina Fog,
H. Lundbeck A/S, Denmark
Session Chair
Session Chair
Joseph W. Lewcock,
Denali Therapeutics, USA
Therapeutic Strategies Based on Human Genetics
Therapeutic Strategies Based on Human Genetics
Matthew Kennedy,
Merck Research Labs, USA
Discovery and Development of LRRK2 Inhibitors
Discovery and Development of LRRK2 Inhibitors
Coffee Break
David V. Hansen,
Brigham Young University, USA
Microglial Activation States in Alzheimer's Disease: Are You a (Wo)man or a Mouse?
Microglial Activation States in Alzheimer's Disease: Are You a (Wo)man or a Mouse?
Jeffrey L. Cleland,
Orpheris, Inc., USA
Short Talk: OP-101: Human Safety and Pharmacokinetics of a Microglia-targeted Systemic Therapy for Neuroinflammation
Short Talk: OP-101: Human Safety and Pharmacokinetics of a Microglia-targeted Systemic Therapy for Neuroinflammation
Anna Ettorre,
4D Pharma Research Ltd., UK
Short Talk: From Screening to Pre-Clinical Efficacy of Microbiome-Derived Bacterial Strains that Modulate Neuroinflammatory and Neurodegenerative Processes in Parkinson's Disease
Short Talk: From Screening to Pre-Clinical Efficacy of Microbiome-Derived Bacterial Strains that Modulate Neuroinflammatory and Neurodegenerative Processes in Parkinson's Disease
Garrett S. Gibbons,
University of Pennsylvania, USA
Short Talk: Conformation-Selective Tau Monoclonal Antibodies as Immunotherapy Candidates for Alzheimer's Disease (AD) and Frontotemporal Lobar Degeneration-tau (FTLD-tau)
Short Talk: Conformation-Selective Tau Monoclonal Antibodies as Immunotherapy Candidates for Alzheimer's Disease (AD) and Frontotemporal Lobar Degeneration-tau (FTLD-tau)
08:30—11:45
Glymphatics and Lymphatics
*
Kari K. Alitalo,
University of Helsinki, Finland
CNS Lymphatics
CNS Lymphatics
Coffee Break
Maria Lehtinen,
Harvard Medical School, USA
Orchestration of Embryonic Brain Development by the Choroid Plexus
Orchestration of Embryonic Brain Development by the Choroid Plexus
*
Julie Siegenthaler,
University of Colorado Denver, USA
Meningeal Fibroblast Identity and Function: New Insights from scRNA-Sequencing
Meningeal Fibroblast Identity and Function: New Insights from scRNA-Sequencing
Percy Griffin,
Washington University in St. Louis, USA
Short Talk: Circadian Regulation of Neuroinflammation and Neurodegeneration by Rev-Erba
Short Talk: Circadian Regulation of Neuroinflammation and Neurodegeneration by Rev-Erba
Celia McKee,
Washington University in St. Louis, USA
Short Talk: The Astrocyte Circadian Clock Regulates Amyloid Beta Deposition and Degradation
Short Talk: The Astrocyte Circadian Clock Regulates Amyloid Beta Deposition and Degradation
Caio Mazucanti,
NIA, National Institutes of Health, USA
Short Talk: Serotonergic Regulation of Insulin Expression & Release in Choroid Plexus
Short Talk: Serotonergic Regulation of Insulin Expression & Release in Choroid Plexus
14:30—16:30
Round Table Discussion from Industry, Government and Academia - Challenges and Opportunities
*
Joseph W. Lewcock,
Denali Therapeutics, USA
Session Chair
Session Chair
Gene W. Yeo,
University of California, San Diego, USA
Matthew Kennedy,
Merck Research Labs, USA
Frank Rigo,
Ionis Pharmaceuticals, USA
Amir Tamiz,
NINDS, National Institutes of Health, USA
Aaron D. Gitler,
Stanford University School of Medicine, USA
17:00—19:00
Molecular Mechanisms of ALS/FTD
*
Shanthini Sockanathan,
Johns Hopkins University School of Medicine, USA
Session Chair
Session Chair
Aaron D. Gitler,
Stanford University School of Medicine, USA
Expanding Mechanisms and Therapeutic Targets for Neurodegenerative Disease
Expanding Mechanisms and Therapeutic Targets for Neurodegenerative Disease
Clotilde Lagier-Tourenne,
Massachusetts General Hospital, USA
Molecular Mechanisms of Disease in ALS and FTD
Molecular Mechanisms of Disease in ALS and FTD
Gene W. Yeo,
University of California, San Diego, USA
Protein-RNA and Stress Granules Dysregulation in ALS
Protein-RNA and Stress Granules Dysregulation in ALS
Hideyuki Takahashi,
Yale University, USA
Short Talk: Progranulin Deficiency Induces Expression of Microglial TYROBP Gene Network and Differentially affects Alzheimer's disease pathologies
Short Talk: Progranulin Deficiency Induces Expression of Microglial TYROBP Gene Network and Differentially affects Alzheimer's disease pathologies
Evangelos Kiskinis,
Northwestern University Feinberg School of Medicine, USA
Short Talk: Nucleocytoplasmic Proteomic Analysis Highlights ETF1 and Nonsense Mediated Decay as Therapeutic Targets in C9ORF72-Related ALS/FTD
Short Talk: Nucleocytoplasmic Proteomic Analysis Highlights ETF1 and Nonsense Mediated Decay as Therapeutic Targets in C9ORF72-Related ALS/FTD
17:00—19:00
Adaptive Immune Responses
Vanda A. Lennon,
Mayo Clinic, USA
Astrocytic and Oligodendroglial Autoimmunity
Astrocytic and Oligodendroglial Autoimmunity
*
Daniel S. Reich,
NINDS, National Institutes of Health, USA
Imaging Lesion Repair in Multiple Sclerosis
Imaging Lesion Repair in Multiple Sclerosis
*
Jorge I. Alvarez,
University of Pennsylvania, USA
CNS Intrinsic Mechanisms Suppressing T Cell Driven Neuroinflammation
CNS Intrinsic Mechanisms Suppressing T Cell Driven Neuroinflammation
Keita Saeki,
National Institutes of Health, USA
Short Talk: IRF8 Shapes Long-Term Endotoxin Memory in Microglia
Short Talk: IRF8 Shapes Long-Term Endotoxin Memory in Microglia
Tiffany J. Petrisko,
West Virginia University, USA
Short Talk: CXCL10-CXCR3 Axis Mediates Induction of Cerebral Hyperexcitability by Peripheral Viral Challenge
Short Talk: CXCL10-CXCR3 Axis Mediates Induction of Cerebral Hyperexcitability by Peripheral Viral Challenge
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:30—11:30
Drivers of Synaptic Loss in Disease
*
Clotilde Lagier-Tourenne,
Massachusetts General Hospital, USA
Session Chair
Session Chair
Paul F. Worley,
Johns Hopkins School of Medicine, USA
Immediate Early Genes and Alzheimer's Disease
Immediate Early Genes and Alzheimer's Disease
Beth Stevens,
Boston Children's Hospital, Harvard Medical School, USA
Dynamic Microglia States and Functions in Health & Disease
Dynamic Microglia States and Functions in Health & Disease
Coffee Break
Karen Hsiao Ashe,
University of Minnesota, USA
Synaptic and Cognitive Dysfunction from Non-fibrillar Tau
Synaptic and Cognitive Dysfunction from Non-fibrillar Tau
Shanthini Sockanathan,
Johns Hopkins University School of Medicine, USA
Control of ADAM10 α-Secretase Cleavage of Amyloid Precursor Protein by GDE2-RECK
Control of ADAM10 α-Secretase Cleavage of Amyloid Precursor Protein by GDE2-RECK
Ryan Douglas Hallam,
Brock University, Canada
Short Talk: Synuclein Fibrils Inhibit Synaptic Function in Cortical Neurons through Induction of Nitrosative Stress
Short Talk: Synuclein Fibrils Inhibit Synaptic Function in Cortical Neurons through Induction of Nitrosative Stress
Claire E. Le Pichon,
NICHD, National Institutes of Health, USA
Short Talk: Enhancing the Benefits of DLK Inhibition in a Mouse Model of ALS by Restoring an Adaptive Neuronal Response
Short Talk: Enhancing the Benefits of DLK Inhibition in a Mouse Model of ALS by Restoring an Adaptive Neuronal Response
08:30—11:30
Oligodendrocytes and Inflammation
David H. Rowitch,
University of Cambridge, UK
Neuronal Vulnerability and Multilineage Diversity in Multiple Sclerosis
Neuronal Vulnerability and Multilineage Diversity in Multiple Sclerosis
*
Kelly Monk,
Oregon Health & Science University, USA
Molecular and Genetic Mechanisms of Myelin Formation and Repair
Molecular and Genetic Mechanisms of Myelin Formation and Repair
Coffee Break
Dimitry Ofengeim,
Sanofi, USA
Understanding the Nature of Microglial Phenotypes through the Interplay of Cell Death and Inflammation
Understanding the Nature of Microglial Phenotypes through the Interplay of Cell Death and Inflammation
Stefan Berghoff,
Max-Planck Institut for Experimental Medicine, Germany
Short Talk: Cell-Type Specific Cholesterol Synthesis Coordinates Inflammation and Remyelination in Demyelinated Lesions
Short Talk: Cell-Type Specific Cholesterol Synthesis Coordinates Inflammation and Remyelination in Demyelinated Lesions
Claudia Fuchs,
University of Bologna, Italy
Short Talk: Loss of CDKL5 Enhances Microglia Activation: Are Neuro-Inflammatory Mechanisms Implicated in the Pathophysiology of CDKL5 Deficiency Disorder?
Short Talk: Loss of CDKL5 Enhances Microglia Activation: Are Neuro-Inflammatory Mechanisms Implicated in the Pathophysiology of CDKL5 Deficiency Disorder?
TrangKimberly T. Nguyen,
Emory University, USA
Short Talk: Proteomic Analyses Reveal that Glia-Specific and Seizure-Protective Receptors GPR37L1 and GPR37 Regulate S100A Calcium-Binding Protein Expression and Secretion
Short Talk: Proteomic Analyses Reveal that Glia-Specific and Seizure-Protective Receptors GPR37L1 and GPR37 Regulate S100A Calcium-Binding Protein Expression and Secretion
15:00—16:30
Workshop 2
*
Katerina Akassoglou,
University of California, San Francisco, USA
Session Chair
Session Chair
Irina Alexandra Leaf,
Biogen, USA
Reverse Translational Multimodal Approach to Identify CSF Signatures Associated with Disease Progression in MS
Reverse Translational Multimodal Approach to Identify CSF Signatures Associated with Disease Progression in MS
Chelsey J. LeBlang,
Harvard Medical School, USA
Modulation of the Inflammatory Response by the RNA-binding Protein TIA1 in the P301S Mouse Model of Tauopathy
Modulation of the Inflammatory Response by the RNA-binding Protein TIA1 in the P301S Mouse Model of Tauopathy
Yihang Li,
Dana-Farber Cancer Institute, USA
SARM1 Interacts with the Bclw/IP3R Pathway in Paclitaxel-Induced Axon Degeneration
SARM1 Interacts with the Bclw/IP3R Pathway in Paclitaxel-Induced Axon Degeneration
Michael A. Lodato,
Boston Children's Hospital, USA
Single-Cell, Whole-Genome Sequencing Reveals Mechanisms of DNA Damage and Somatic Mutation in the Human Brain during Aging and in Neurodegeneration
Single-Cell, Whole-Genome Sequencing Reveals Mechanisms of DNA Damage and Somatic Mutation in the Human Brain during Aging and in Neurodegeneration
Michaela O. Lunn,
Carleton University, Canada
Contribution of Lrrk2 to the Modulation of Host Immunity during Infection
Contribution of Lrrk2 to the Modulation of Host Immunity during Infection
Jing Yang,
Peking University, China
Local Degeneration of Catecholaminergic Axons Acts as the Protective Mechanism in Colitis
Local Degeneration of Catecholaminergic Axons Acts as the Protective Mechanism in Colitis
Samara Reck-Peterson,
University of California, San Diego, USA
A Structural and Mechanistic Model for the Regulation of LRRK2's Interaction with Microtubules
A Structural and Mechanistic Model for the Regulation of LRRK2's Interaction with Microtubules
14:30—16:30
Workshop 2: Astrocyte-Microglia Crosstalk during Inflammation
*
Blanca Diaz Castro,
University of Edinburgh, UK
Session Chair
Session Chair
Lilianne Barbar,
New York Stem Cell Foundation Research Institute, USA
Developing in vitro Models of Neurodegeneration Based on Human iPSC-Derived Astrocytes
Developing in vitro Models of Neurodegeneration Based on Human iPSC-Derived Astrocytes
Cristina Gutierrez-Vazquez,
Harvard Medical School, USA
EphrinB3 Signaling Promotes Pathogenic Activities in Astrocytes during Central Nervous System Inflammation
EphrinB3 Signaling Promotes Pathogenic Activities in Astrocytes during Central Nervous System Inflammation
Weikang Cai,
Joslin Diabetes Center, USA
Insulin Signaling-Dependent ATP Release from Astrocytes is Important for Dopamine Release and Depressive-Like Behavior
Insulin Signaling-Dependent ATP Release from Astrocytes is Important for Dopamine Release and Depressive-Like Behavior
Elena Blanco-Suarez,
The Salk Institute for Biological Studies, USA
Astrocyte-Secreted Chrdl1 Promotes Synapse Maturation and Limits Synaptic Plasticity through GluA2-AMPAR Increase
Astrocyte-Secreted Chrdl1 Promotes Synapse Maturation and Limits Synaptic Plasticity through GluA2-AMPAR Increase
Martín M. Riccomagno,
University of California, Riverside, USA
Novel Combinatorial Approaches to Selectively Target Reactive Astrocytes
Novel Combinatorial Approaches to Selectively Target Reactive Astrocytes
Kun Leng,
University of California, San Francisco, USA
Mapping Pathways Controlling the Reactive State of Astrocytes through CRISPRi Loss-of-Function Screening and Single-Cell RNA-Seq
Mapping Pathways Controlling the Reactive State of Astrocytes through CRISPRi Loss-of-Function Screening and Single-Cell RNA-Seq
Deepa Jonnalagadda,
Sanford Burnham Prebys Medical Discovery Institute, USA
Sphingosine 1-Phosphate Signaling Effects in Immediate-Early Astrocytes (ieAstrocytes)
Sphingosine 1-Phosphate Signaling Effects in Immediate-Early Astrocytes (ieAstrocytes)
17:00—18:45
Glial Contributors to Neurodegeneration
*
Beth Stevens,
Boston Children's Hospital, Harvard Medical School, USA
Session Chair
Session Chair
Mathew M. Blurton-Jones,
University of California, Irvine, USA
Development of a Chimeric Model to Study and Manipulate Human Microglia in vivo
Development of a Chimeric Model to Study and Manipulate Human Microglia in vivo
Katerina Akassoglou,
University of California, San Francisco, USA
Neurovascular Interactions: Mechanisms, Imaging, Therapeutics
Neurovascular Interactions: Mechanisms, Imaging, Therapeutics
Anastasia Efthymiou,
Icahn School of Medicine at Mount Sinai, USA
Short Talk: Investigating the Effect of the MS4A locus on Alzheimer's Disease Risk
Short Talk: Investigating the Effect of the MS4A locus on Alzheimer's Disease Risk
17:00—18:45
Hot Topics
Erik M. Ullian,
University of California, San Francisco, USA
Novel Three-Dimensional Astrocyte-Containing Organoids Recapitulate Key Aspects of Human Neurodegenerative Disease
Novel Three-Dimensional Astrocyte-Containing Organoids Recapitulate Key Aspects of Human Neurodegenerative Disease
*
Long-Jun Wu,
Mayo Clinic, USA
Neuronal Network Activity Controls Microglial Process Surveillance in Awake Mice via Norepinephrine Signaling
Neuronal Network Activity Controls Microglial Process Surveillance in Awake Mice via Norepinephrine Signaling
*
Yi Ren,
Florida State University, USA
The Inflammatory Mechanisms Involved in Myelin-Debris-Induced Pathological Changes in Neural Injury
The Inflammatory Mechanisms Involved in Myelin-Debris-Induced Pathological Changes in Neural Injury
Julia A. Kuhn,
Alector Inc, USA
Short Talk: Sex Differences in Microglial Contributions to Pain
Short Talk: Sex Differences in Microglial Contributions to Pain
18:45—19:00
Meeting Wrap-Up: Outcomes and Future Directions
Valina L. Dawson,
Johns Hopkins University School of Medicine, USA
Joseph W. Lewcock,
Denali Therapeutics, USA
Fred H. Gage,
The Salk Institute for Biological Studies, USA
18:45—19:00
Meeting Wrap-Up: Outcomes and Future Directions
Vanda A. Lennon,
Mayo Clinic, USA
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
20:00—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.
*Session Chair †Invited, not yet responded.
We gratefully acknowledge support for this conference from:
Keystone Symposia thanks our Sponsors(s) for generously supporting this meeting:
|
|
|
|
|
|
|
|
We gratefully acknowledge additional support from these exhibitors at this conference:
|
|
|
|
Please stop by to meet these exhibitors during the conference.
We gratefully acknowledge the generous grant for this conference provided by:
We gratefully acknowledge additional support for this conference from:
|
|
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: John Monson,
Director of Corporate Relations, Email: johnm@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org, Phone:+1 970-262-1179 |
